Day #2 of the BIO CEO & Investor Conference was all about the future. How can we ensure the workforce reflects the diverse demographics of the patients the industry serves? What does the future of biotech investment look like? How can we incentivize innovation? Here are some takeaways from …

Last month, the Biotechnology Innovation Organization (BIO) released the first annual report measuring diversity and inclusion in the biotech industry, with real, practical solutions for making the biotech workforce more representative of the industry’s customers and patients. During the BIO CEO …

We’re seeing an “extraordinary level” of biotech innovation, said BIO Chair Jeremy Levin, CEO of Ovid Therapeutics Inc., while kicking off the 22nd BIO CEO & Investor Conference on February 10th in New York. Day #1 of the conference featured discussions about the breakthrough therapies of the…

“The promise for patients has never been better from a scientific point of view,” said BIO CEO and former Member of Congress Jim Greenwood, speaking at the 22nd BIO CEO & Investor Conference in New York. “But it’s the worst of times politically.” Specifically: There are “mountains of political…

As the biotech industry advances scientific discovery around new tumor types and mechanisms of action, we’ve seen more than 2,000 combination trials launched to enhance PD-1/L1 checkpoint inhibitors’ effects on solid tumors. The oncology pipeline has some exciting new biotechnological approaches…

The 22nd annual BIO CEO & Investor Forum kicked off today with a Welcome and Update on BIO's 2020 Initiatives on Behalf of the Industry given by Jeremy Levin, CEO of Ovid Therapeutics Chair of the Board of Directors of BIO. The industry was established in 1970’s during an era of bipartisan…

BIO’s Industry Analysis team has published its 5th report in a series on the innovation landscape of highly prevalent, chronic diseases. This new report [available here] reviews the state of drug development for hypertension and heart failure. As with the prior reports, the investigation into these…

For nearly two decades, the BIO World Congress has served as a catalyst to the growth and evolution of the bioeconomy. From the conversations started in BIO One-on-One PartneringTM that have led to critical partnerships, to the emerging company presentations that spurred investment, the conference…

As a new college graduate in the early 80’s, Shawn Tomasello knew one thing for sure. She wanted a career in an industry that would constantly change; one that would keep her on her toes; allow her to always be learning.  At a career fair during her senior year, she discovered Pfizer Laboratories…

Negotiating successful deals is a critical skill for biopharma companies hoping to bring their medical breakthroughs and treatment options to the patients around the globe who need them.  Along the way emerging biotechs need financial and strategic partners to help support thier efforts. While…